TicoVac 0.5 ml Suspension for injection in a pre-filled syringeTick-Borne Encephalitis Vaccine (whole Virus, inactivated) Ireland - English - HPRA (Health Products Regulatory Authority)

ticovac 0.5 ml suspension for injection in a pre-filled syringetick-borne encephalitis vaccine (whole virus, inactivated)

pfizer healthcare ireland - tbe virus antigen - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - encephalitis vaccines; encephalitis, tick borne, inactivated, whole virus - encephalitis vaccines - it is indicated for the active (prophylactic) immunization of persons of 16 years of age and older against tick-borne encephalitis (tbe).

JESPECT Japanese encephalitis virus purified inactivated vaccine 0.5mL suspension for injection syringe Australia - English - Department of Health (Therapeutic Goods Administration)

jespect japanese encephalitis virus purified inactivated vaccine 0.5ml suspension for injection syringe

seqirus pty ltd - japanese encephalitis virus, quantity: 6 agu - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate; water for injections - jespect is indicated for active immunisation against japanese encephalitis (je) virus for persons 18 years of age and older. jespect should be considered for use in persons who plan to reside in or travel to areas where je is endemic (common) or epidemic (seasonal), especially during the transmission season. jespect is indicated for persons who work with je virus in laboratories and in industry.

TICOVAC 0.5 ML Ireland - English - HPRA (Health Products Regulatory Authority)

ticovac 0.5 ml

baxter vaccine ag - tbe virus antigen - suspension for injection

TICOVAC JUNIOR 0.25 ML Ireland - English - HPRA (Health Products Regulatory Authority)

ticovac junior 0.25 ml

baxter vaccine ag - tbe virus antigen - suspension for injection

Jcovden (previously COVID-19 Vaccine Janssen) European Union - English - EMA (European Medicines Agency)

jcovden (previously covid-19 vaccine janssen)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vaccines - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older.the use of this vaccine should be in accordance with official recommendations.

FSME-IMMUN Suspension for Injection 0.5 Millilitre Ireland - English - HPRA (Health Products Regulatory Authority)

fsme-immun suspension for injection 0.5 millilitre

baxter vaccine ag - tbe virus antigen - suspension for injection - 0.5 millilitre

PreHevbri European Union - English - EMA (European Medicines Agency)

prehevbri

vbi vaccines b.v. - hepatitis b surface antigen - hepatitis b - vaccines - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.,

IXIARO Suspension for Injection 0.5ml in pre-filled syringe Singapore - English - HSA (Health Sciences Authority)

ixiaro suspension for injection 0.5ml in pre-filled syringe

aenon pharmaceuticals sea pte. ltd. - japanese encephalitis virus strain sa₁₄-14-2 (inactivated) - injection, suspension - 6 μg/0.5 ml - japanese encephalitis virus strain sa₁₄-14-2 (inactivated) 6 μg/0.5 ml